Clinical Trial Update: Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of apatinib and etoposide in platinum-resistant or refractory ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Apatinib (apatinib)
• Etoposide (Etoposide)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED